Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report)'s share price was down 4.4% on Wednesday following insider selling activity. The company traded as low as $28.63 and last traded at $28.70. Approximately 280,362 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 305,168 shares. The stock had previously closed at $30.01.
Specifically, insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction on Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the completion of the transaction, the insider now directly owns 94,622 shares in the company, valued at approximately $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
A number of research firms recently weighed in on CSTL. Robert W. Baird increased their price objective on Castle Biosciences from $34.00 to $37.00 and gave the company an "outperform" rating in a report on Tuesday, August 6th. Stephens reaffirmed an "overweight" rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, August 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences currently has an average rating of "Buy" and an average target price of $32.80.
Check Out Our Latest Report on CSTL
The company has a market cap of $792.32 million, a P/E ratio of -26.10 and a beta of 1.03. The stock's 50-day moving average price is $28.36 and its 200-day moving average price is $24.03. The company has a current ratio of 8.12, a quick ratio of 7.92 and a debt-to-equity ratio of 0.02.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.47. The company had revenue of $87.00 million for the quarter, compared to analysts' expectations of $69.95 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same quarter in the prior year, the firm earned ($0.70) EPS. As a group, research analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in CSTL. Birchview Capital LP acquired a new stake in shares of Castle Biosciences in the 4th quarter worth about $216,000. Parkman Healthcare Partners LLC raised its holdings in shares of Castle Biosciences by 59.0% in the 4th quarter. Parkman Healthcare Partners LLC now owns 357,156 shares of the company's stock worth $7,707,000 after acquiring an additional 132,564 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Castle Biosciences by 89.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,862 shares of the company's stock worth $241,000 after acquiring an additional 5,123 shares during the last quarter. Denali Advisors LLC purchased a new stake in Castle Biosciences in the 1st quarter valued at about $186,000. Finally, Norden Group LLC purchased a new stake in Castle Biosciences in the 1st quarter valued at about $547,000. Institutional investors and hedge funds own 92.60% of the company's stock.
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.